SCHEDULE: Millennium Management Reduces Avalo Therapeutics Stake

Millennium Management LLC and affiliates disclosed a 4.9% beneficial ownership in Avalo Therapeutics, Inc., indicating a reduction below the 5% reporting threshold.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander reported beneficial ownership of 906,762 shares of Avalo Therapeutics, Inc. common stock.
• This represents 4.9% of the company's outstanding common stock.
• The reporting persons initially acquired more than 5% beneficial ownership on February 3, 2026, but subsequently ceased to hold more than 5% by the filing date of February 9, 2026.
• The filing is a Schedule 13G, indicating passive investment intent, not seeking to influence control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a moderately negative signal, as a prominent institutional investor has reduced its stake below the 5% reporting threshold, potentially indicating a less favorable outlook on the company.

Positives

• The filing indicates that Millennium Management LLC and its affiliates are passive investors, not seeking to influence control of Avalo Therapeutics, Inc.

Negatives

• Millennium Management LLC and its affiliates reduced their beneficial ownership in Avalo Therapeutics, Inc. from over 5% to 4.9% between February 3, 2026, and February 9, 2026.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

StockSavvy.ai notes that a reduction in a significant institutional stake, particularly by a prominent hedge fund like Millennium Management, can sometimes signal a shift in investor sentiment or a re-evaluation of the company's prospects. While the filing itself is a routine disclosure, the underlying transaction of reducing ownership below the 5% threshold could be interpreted by the market as a less bullish stance on Avalo Therapeutics compared to its peers in the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: May interpret the reduction in stake by a major institutional investor as a negative signal, potentially leading to downward pressure on the stock price.

Key Dates

Recommendation

The reduction of a significant institutional stake by Millennium Management LLC, a prominent hedge fund, from over 5% to 4.9% suggests a diminished conviction in Avalo Therapeutics. Such a move by a sophisticated investor can signal potential headwinds or a less favorable outlook, prompting a 'sell' recommendation for investors to consider reducing their exposure.

Keywords

Avalo Therapeutics, Millennium Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake, Passive Investment